Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes

Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Biagio Arcidiacono, Domenica Maria Corigliano, Stefania Giuliano, Francesco Saverio Brunetti, Sinan Tanyolaç, Daniela Patrizia Foti, Luigi Puccio and Antonio Brunetti
Additional contact information
Maria Mirabelli: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Eusebio Chiefari: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Patrizia Caroleo: Complex Operative Structure Endocrinology-Diabetology, Hospital Pugliese-Ciaccio, 88100 Catanzaro, Italy
Biagio Arcidiacono: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Domenica Maria Corigliano: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Stefania Giuliano: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Francesco Saverio Brunetti: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Sinan Tanyolaç: Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Biruni University, 34010 Istanbul, Turkey
Daniela Patrizia Foti: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy
Luigi Puccio: Complex Operative Structure Endocrinology-Diabetology, Hospital Pugliese-Ciaccio, 88100 Catanzaro, Italy
Antonio Brunetti: Department of Health Sciences, University “Magna Græcia” of Catanzaro, 88100 Catanzaro, Italy

IJERPH, 2019, vol. 17, issue 1, 1-11

Abstract: Background : Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) based on the human GLP-1 sequence, with potential weight loss benefits, approved for the treatment of type 2 diabetes (T2D) mellitus. Herein, we aimed to assess the 5-year effectiveness of Liraglutide in the management of weight and glycometabolic control in a Southern Italian cohort of overweight/obese T2D patients, who were naïve to GLP-1 RAs. Patients and Methods : Forty overweight or obese patients treated with Liraglutide at doses up to 1.8 mg/day, in combination with one or more oral antidiabetic agents, were retrospectively assessed at baseline, during, and after 60 months of continuous therapy. Results : After 5 years of Liraglutide treatment, body weight decreased from 92.1 ± 20.5 kg to 87.3 ± 20.0 Kg ( p < 0.001), with a mean reduction of 5.0 ± 7.0 Kg and a body mass index (BMI) decrement of −2.0 ± 3.1 Kg/m 2 . On Spearman’s univariate analysis, change in body weight was correlated with female gender and baseline BMI. Hemoglobin A1c (HbA1c) decreased from 7.9 ± 0.9% at baseline to 7.0 ± 0.7% at the end of the study period ( p < 0.001), followed by a significant reduction in fasting plasma glucose. No significant differences emerged in other biochemical parameters, despite a trend toward improvement in lipid profile. Notwithstanding encouraging effects on several markers of cardiovascular disease (CVD), increments in the 5- and 10-year risk for the first atherosclerotic cardiovascular event were documented, as four incident cases of myocardial infarction. Conclusions : Prolonging treatment with Liraglutide can lead to durable benefits in relation to weight and glycemic control, with a greater impact on women. These results extend and corroborate previous observations, suggesting that gender per se may modulate the response to Liraglutide. Despite favorable effects on some established CVD risks factors, the long-term role of Liraglutide in primary prevention of CVD in patients with T2D remains controversial.

Keywords: gender difference; liraglutide; weight management; type 2 diabetes (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/1/207/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/1/207/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2019:i:1:p:207-:d:302583

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().